Structural & Congenital Heart Disease

The FDA has approved the third generation of the MitraClip, which treats mitral regurgitation without open-heart surgery, device manufacturer Abbott announced July 12.

Scientists are beginning to explore whether infusing heart tissue with mitochondria can restore function to oxygen-deprived cells after a heart attack. The technique has potential in both pediatric and adult patients, according to an article in The New York Times.

Nearly all transcatheter heart valves (THVs) leave debris following aortic valve replacement, reinforcing the potential for embolic protection devices to reduce the burden of silent brain infarctions and future strokes.

CMS is taking public comments ahead of a Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) meeting July 25 in which panelists will discuss procedural volume requirements for centers to begin and maintain a transcatheter aortic valve replacement (TAVR) program.

Nitric oxide administration during and after multiple-valve heart surgery significantly reduced patients’ chances of developing acute and chronic kidney problems, according to a randomized trial published in the American Journal of Respiratory and Critical Care Medicine.

Transcatheter valve-in-valve replacement for degenerated mitral bioprostheses was associated with similar 30-day and one-year mortality rates as redo surgical mitral valve replacement (SMVR) in a retrospective study, despite the former being performed in older, sicker patients.

Mutations in the CHD4 gene are known contributors to congenital heart defects. Biologists at the University of North Carolina School of Medicine believe they are beginning to understand why.

Coronary artery bypass graft (CABG) surgeries, in particular, were strongly linked to the life-threatening condition—carrying a 14-fold increase in relative risk, among the top five of all inpatient procedures analyzed.

Acute kidney injury (AKI) occurs in about 9 percent of patients undergoing left atrial appendage closure (LAAC) and is associated with greater odds of downstream mortality and embolic events, according to a study published June 4 in JACC: Cardiovascular Interventions.

Patients who required permanent pacemakers (PPMs) after transcatheter aortic valve replacement (TAVR) demonstrated lower survival rates and higher comorbidity burdens over a multiyear follow-up. However, they didn’t accumulate significantly greater healthcare costs, according to a study published online May 25 in JAMA Network Open.

An investigational transcatheter mitral valve replacement (TMVR) device helped reduce mitral regurgitation to zero or trace levels in 98.7 percent of patients, according to 30-day follow-up data from the first 100 people scheduled to be treated with Abbott’s Tendyne system.

Despite being performed in an older population with more cardiovascular comorbidities, transcatheter aortic valve replacement (TAVR) demonstrated similarly low rates of postoperative stroke and mortality compared with surgical aortic valve replacement (SAVR) in a study of patients with previous strokes.